Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Reticulon-1 (RTN1)
- Target
- RTN1
- Molecular classification
- Integral membrane protein, Reticulon family, Endoplasmic reticulum protein, Other
01
Overview
Reticulon-1 is an integral membrane protein most commonly localized to the tubular regions of the endoplasmic reticulum, where it helps generate and stabilize the tubular ER network. It contains a conserved Reticulon Homology Domain (RHD) with two long hydrophobic segments, and can oligomerize. Reticulon-1 regulates key cellular functions such as ER organization, nuclear envelope formation, calcium homeostasis, apoptosis, and autophagy. Dysregulation of reticulon proteins, in particular RTN-1C, has been implicated in the development of cancer and a range of neurodegenerative diseases, where it may serve as a biomarker or therapeutic target. Reticulon-1 can modulate enzymes like HDACs and PDIs, affecting processes like protein folding and aggregation in neurodegeneration.
- Other names
- Reticulon-1RTN1Neuroendocrine-specific proteinNSPReticulon-1C
02
Mechanism of action
Modulation of protein-protein interactions (e.g., regulation of PDI function via S-nitrosylation); Regulation of ER structure to influence apoptosis, autophagy, and cellular stress responses; Impact on calcium flux and mitochondrial dynamics
03
Biological functions
Regulation of ER morphology and organizationER-stress-mediated cell deathApoptosisRegulation of calcium homeostasisMembrane trafficking (endo/exocytosis)Nuclear envelope formation during mitosisAutophagyGene expression modulation
04
Disease associations
Cancer (especially neuroendocrine tumors)Neurodegenerative diseases (Alzheimer’s disease, amyotrophic lateral sclerosis, Parkinson’s disease, Huntington’s disease, prion diseases, hereditary spastic paraplegias)Schizophrenia (related to calcium homeostasis)
05
Safety considerations
Potential challenges in targeting Reticulon-1 safely arise from its role in essential cellular processes like ER morphology and cell survival, implying that inhibition may disrupt normal neuronal or cancer cell homeostasisTargeting ER stress pathways may have broad, non-specific effects leading to toxicity
06
Biomarkers
Altered Reticulon-1C expression (e.g., decreased in Alzheimer’s disease frontal cortex)Dysregulation observed in certain cancers and neurodegenerative disorders, suggesting possible use as a tissue biomarker
Beyond the preview
Go deeper on Reticulon-1 (RTN1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reticulon-1 (RTN1).